Pharmaceutical News

RSS

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.

31 Mar 2015

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets.

31 Mar 2015

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Aeterna Zentaris Inc. today announced that it has agreed to transfer its discovery library of roughly 100,000 unique compounds to the South Carolina Center for Therapeutic Discovery & Development (the Center) pursuant to a just concluded Material Transfer Agreement.

31 Mar 2015

Study provides new estimates of opioid misuse, addiction

New estimates suggest that 20 to 30 percent of opioid analgesic drugs prescribed for chronic pain are misused, while the rate of opioid addiction is approximately 10 percent, reports a study in the April issue of PAIN, the official journal of the International Association for the Study of Pain.

31 Mar 2015

New analysis raises questions about common use of antidepressant drugs for anxiety disorders

A new analysis reported in JAMA Psychiatry raises serious questions about the increasingly common use of second-generation antidepressant drugs to treat anxiety disorders.

31 Mar 2015

New HCV therapies cost-effective in specific groups of HCV-infected patients

A study led by Boston Medical Center researchers demonstrates that while new therapies to treat Hepatitis C Virus (HCV) are highly effective, they are cost-effective and provide the greatest value in specific groups of HCV-infected patients.

31 Mar 2015

Less-toxic drug combined with fasting may kill cancer cells

Fasting in combination with chemotherapy has already been shown to kill cancer cells, but a pair of new studies in mice suggests that a less-toxic class of drugs combined with fasting may kill breast, colorectal and lung cancer cells equally well.

31 Mar 2015

Study reveals link between dietary magnesium intake and diabetes-related health outcomes

A recent analysis published in the Journal of Human Nutrition & Food Science reveals a beneficial relationship between dietary magnesium intake and diabetes-related outcomes including decreased risk for metabolic syndrome, obesity or overweight, elevated blood pressure, and reduced HDL (good) cholesterol.

31 Mar 2015

Useful tips for physicians to help patients make the right choice on statin drugs

Cholesterol-lowering statins have transformed the treatment of heart disease. But while the decision to use the drugs in patients with a history of heart attacks and strokes is mostly clear-cut, that choice can be a far trickier proposition for the tens of millions of Americans with high cholesterol but no overt disease.

31 Mar 2015

New oral drug shows promise in patients with chronic kidney disease

Patients with chronic kidney disease may be treated with a class of medications called Renin Angiotensin Aldosterone System inhibitors (RAASI's). Although these drugs protect the heart and kidney, a significant percentage of patients develop a dangerous side effect -- high potassium levels in the blood (hyperkalemia).

31 Mar 2015

New drug shows potential against rare type of acute leukemia

Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug that shows potential in laboratory studies against a rare type of acute leukemia. And additional studies suggest the same compound could play a role in prostate cancer treatment as well.

30 Mar 2015

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Researchers at the Blanchette Rockefeller Neurosciences Institute and the Marshall University Joan C. Edwards School of Medicine announced their findings from a new study entitled, "PSEN1 Variant in a Family with Atypical AD." An Alzheimer patient with very severe disease, genetically confirmed to have a known variant of PSEN1, showed promising benefits during treatment with the drug Bryostatin 1.

30 Mar 2015

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies.

30 Mar 2015

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

The investigational S-equol nutritional supplement may be a viable agent to alleviate certain menopause symptoms, such as hot flashes, according to a new peer-reviewed article in the March Journal of Women's Health.

30 Mar 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy.

30 Mar 2015

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Synageva BioPharma Corp., a biopharmaceutical company developing therapeutic products for rare disorders, announced today the submission to the Comisión Federal para la Protección contra Riesgos Sanitarios in Mexico for Kanuma as a treatment for patients with lysosomal acid lipase deficiency (LAL Deficiency), a rare genetic disease with significant morbidity and early mortality.

30 Mar 2015

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Medunik Canada, a Canadian pharmaceutical company specialized in rare diseases, is pleased to announce that PHEBURANE (a tasteless oral formulation of sodium phenylbutyrate), is now available for distribution in Canada. PHEBURANE is the first drug to be approved in Canada for the chronic management of urea cycle disorders (UCD) after receiving market authorisation on January 27th, 2015.

30 Mar 2015

Pain relief from IA injection may not predict better outcomes following arthroscopic hip surgery

How best to treat and recover from complicated hip injuries is a growing field in orthopaedic medicine. While diagnostic hip injections are commonly performed for patients with labral tear to confirm the pain etiology, research presented today at the American Orthopaedic Society for Sports Medicine's Specialty Day suggests that pain relief from this diagnostic injection may not predict better outcomes following arthroscopic hip surgery.

30 Mar 2015

Combination treatment improves outcomes in women with ovarian cancer

Medical researchers are always looking for ways to prevent or cure cancer. Given the complexity of this disease, reaching these milestones has been difficult.

30 Mar 2015

APrON study: Pregnant and lactating women not meeting recommended intake of omega-3

Alberta Pregnancy Outcomes and Nutrition (APrON) is a birth cohort involving over two thousand women and their infants from Calgary and Edmonton that was funded by Alberta Innovates Health Solutions and includes researchers at the University of Alberta and the University of Calgary.

30 Mar 2015

Pharmaceutical News

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Aeterna Zentaris inks Material Transfer Agreement with MUSC

Study provides new estimates of opioid misuse, addiction

New analysis raises questions about common use of antidepressant drugs for anxiety disorders

New HCV therapies cost-effective in specific groups of HCV-infected patients

Less-toxic drug combined with fasting may kill cancer cells

Study reveals link between dietary magnesium intake and diabetes-related health outcomes

Useful tips for physicians to help patients make the right choice on statin drugs

New oral drug shows promise in patients with chronic kidney disease

New drug shows potential against rare type of acute leukemia

Patient with severe Alzheimer's shows promising benefits during treatment with Bryostatin drug

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Investigational S-equol nutritional supplement may alleviate certain menopause symptoms

Hospira announces availability of INFLECTRA (infliximab) in Canada

Synageva announces submission of Kanuma application to Cofepris for treatment of LAL Deficiency

Medunik announces availability of PHEBURANE drug in Canada for chronic management of UCD

Pain relief from IA injection may not predict better outcomes following arthroscopic hip surgery

Combination treatment improves outcomes in women with ovarian cancer

APrON study: Pregnant and lactating women not meeting recommended intake of omega-3

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News